Examining Drivers of Cardiac PET CT Perfusion Growth and Flyrcado Adoption

Research evidence excerpt

Examining Drivers of Cardiac PET CT Perfusion Growth and Flyrcado Adoption

eriority and favorable

reimbursement, especially in the office. Flyrcado is acknowledged as a better imaging agent

relative to Rb-82. It has superior signal to noise, dynamic range and spatial localization, facilitating

clearer assessment of perfusion defects, and more accurate blood flow quantification.

Further, unlike Rb-82, Flyrcado is compatible with exercise stress. Studies emphasizing improved

performance of Flyrcado in clinically difficult populations will likely help spur adoption, even in high

volume sites with favorable Rb-82 economics.

3rd party turnkey mobile service providers are key enablers, as they can obviate the need

for capital / manpower investments, esp. for smaller practices. GEHC has announced an

arrangement with CardioNavix, the largest provider, a good sign.

Workflow consequences of Flyrcado’s wait between rest and stress are somewhat problematic. In

our view, GEHC would do well to reliably avail customers of approved correction software that

allows back-to-back rest-stress or develop this internally.

Reimbursement remains attractive as the proposed '27 HOPPS shows PET CT perfusion

transitioning to a permanent code with its advantage intact. While only ~6% of PET CT perfusion Matthew Taylor, CFA * | Equity Analyst

is performed in the OP hospital in FFS patients – extension of the TPT (expires 3.31.28) would help 1 (212) 778-8721 | matt.taylor@jefferies.com

ensure price stability. GEHC might consider taking a page out of the PSMA mfgs playbooks and Young Li * | Equity Analyst

develop a 2.0 version. +1 (212) 778-8671 | young.li@jefferies.com

FY (Dec) 2024A 2025A 2026E 2027E Michael Sarcone, CFA * | Equity Analyst